Canopus Biopharma Inc. Dba Blue Heaven Coffee Inc. Announces and Secures Financial Payment Processing Provider Nayax Ltd. (Nasdaq: NYAX; TASE: NYAX) with a focus on Nayax's CoinBridge Enablement for the Processing of Bitcoin (BTC) and Other Virtual Assets in Unattended Retail Framework

December 7, 2023 7:00 AM

LAS VEGAS, NV / ACCESSWIRE / December 7, 2023 / Canopus Biopharma Inc. (OTC PINK:CBIA) Dba Blue Heaven Coffee Inc. (BHC) is pleased to announce its association with internationally recognized global commerce enablement, payments, and loyalty platform Provider Nayax Ltd. (Nasdaq: NYAX; TASE: NYAX). Nayax offers a complete payment solutions platform including localized cashless payment acceptance, management suite, and consumer engagement tools,...

Read more

QuBind.com Makes Major Strides in T-Cell Immunotherapy with Revolutionary AI Innovation

December 6, 2023 12:30 PM

NEW YORK, NY / ACCESSWIRE / December 6, 2023 / In just 18 months, the young startup QuBind.com has achieved a remarkable breakthrough in T-cell immunotherapy, developing an advanced AI stack that is set to revolutionize personalized medicine. This significant milestone, reached with predominantly bootstrap funding, support from friends, family, and a strategic investment from a handful general partners in the PE sector, underscores the company's...

Read more

Remedy Plan Therapeutics Expands Leadership Team and Board of Directors

December 6, 2023 10:00 AM

GAITHERSBURG, MD / ACCESSWIRE / December 6, 2023 / Remedy Plan Therapeutics ("Remedy Plan"), a small molecule therapeutics start-up company transforming the field of NAMPT inhibition, is pleased to announce the expansion of its leadership team with the appointment of Cassandra Choe-Juliak, M.D., M.S., as the acting Chief Medical Officer (CMO).Dr. Choe-Juliak has more than 17 years of experience in biopharma, most recently as the Chief Medical...

Read more

New Glyphosate and Forever Chemicals Binding Strains Available for Commercialization

December 6, 2023 7:15 AM

Gene Guard Detox, a groundbreaking scientific research company since 2019, has developed a patented revolutionary new product, selected strains for removing glyphosate and plasticizing chemicals (BPA) from the body.PONTE VEDRA BEACH, FL / ACCESSWIRE / December 6, 2023 / Gene Guard Detox is thrilled to announce a glyphosate detox solution that has successfully identified and isolated strains of food-grade bacteria, using in-vitro and in-vivo...

Read more

Adolore BioTherapeutics Presents Promising Preclinical Data Supporting Its Innovative Gene Therapy to Treat Chronic Pain

December 5, 2023 10:30 AM

Innovative rdHSV-based CA8* gene therapy demonstrates preclinical proof-of-concept as a disease-modifying long-acting local analgesic to replace opioids in chronic osteoarthritis (OA) knee pain managementDELRAY BEACH, FL / ACCESSWIRE / December 5, 2023 / Adolore BioTherapeutics ("Adolore" or the "Company"), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain, today announced the...

Read more

First Light Diagnostics Receives FDA Clearance for its Rapid B. anthracis Toxin Test on the MultiPath Analyzer

December 5, 2023 10:00 AM

Rapid, sensitive test for the early diagnosis of inhalation anthraxCHELMSFORD, MA / ACCESSWIRE / December 5, 2023 / First Light Diagnostics announced that the US Food and Drug Administration (FDA) has cleared its SensiTox® B. anthracis Toxin Test to be marketed in the U.S. First Light Diagnostics First Light Diagnostics is developing a range of diagnostic products for early detection of infections to reduce the spread of antibiotic resistance....

Read more

BioInvent Presents Positive First Clinical Data on Anti-FcyRIIB Antibody BI-1607

December 5, 2023 9:30 AM

LUND, SWEDEN / ACCESSWIRE / December 5, 2023 / BioInvent International (STO:BINV)Phase 1 data from 18 patients treated with BI-1607 in combination with trastuzumab presented at San Antonio Breast Cancer SymposiumBI-1607 well tolerated with no serious adverse events, at doses of 75-900mgStable disease have been observed in 6/11 evaluable patients who had previously progressed after trastuzumab containing lines of treatmentBioInvent International...

Read more

Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor's (rosuvastatin) OTC Switch Technology Provider

December 5, 2023 9:15 AM

Idea Evolver is the only provider to successfully complete Actual Use Trial for FDA review for Rx-to-OTC Switch ApprovalNEW YORK, NY / ACCESSWIRE / December 5, 2023 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces its partnership with Idea Evolver (IE), a Technology platform for Rx-to-OTC switches and digital...

Read more

Cytonus Secures Series A Financing to Advance Pipeline of Novel Cargocyte(TM)-Based Medicines

December 5, 2023 9:00 AM

Financing led by Partners Investment, with world-class group of existing and new investors. Pipeline of multiple programs and proprietary Cargocyte™ Drug Delivery Platform to fuel continued portfolio development.SAN DIEGO, CA / ACCESSWIRE / December 5, 2023 / Cytonus Therapeutics, Inc., a U.S.-based biotechnology company discovering and advancing novel medicines enabled by its proprietary Cargocyte™ Drug Delivery Platform, today announced the...

Read more

BioInvent Enrolls First Patient in Phase 1/2a Clinical Trial with TNFR2 Antibody BI-1910

December 5, 2023 7:50 AM

Trial investigates BI-1910 as single agent and in combination with pembrolizumabExploratory expansion cohorts planned in hepatocellular carcinoma and non-small cell lung cancerBioInvent now has five drug candidates in six clinical trials, reflecting productivity of technology platformLUND, SE / ACCESSWIRE / December 5, 2023 / BioInvent International AB ("BioInvent") (STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the discovery...

Read more

DiviTum(R) TKa in Three Posters at the World's Largest Breast Cancer Symposium

December 5, 2023 7:15 AM

UPPSALA, SE / ACCESSWIRE / December 5, 2023 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B) (FRA:9II) Biovica, active in cancer monitoring, today announces that three abstracts based on studies using the blood test DiviTum® TKa will be presented at the world's largest breast cancer symposium, SABCS, in early December.New clinical research for the DiviTum TKa test will be presented at the 2023 San Antonio Breast Cancer Symposium (SABCS)...

Read more

First Patient Enrolled in the PUERTA Phase 2A ARDS Clinical Trial: Treatment with Aqualung Therapeutics ALT-100 mAb

December 5, 2023 7:00 AM

A total of 14 PUERTA participating sites, 12 US and 2 Australian, in the Phase 2A trial of ALT-100 mAb in moderate to severe ARDSAqualung awarded a $3M NIH R44 grant supporting the PUERTA Phase 2A Clinical TrialTUCSON, AZ and JUNO BEACH, FL / ACCESSWIRE / December 5, 2023 / Aqualung Therapeutics, an early stage immunotherapeutics company with an anti-inflammatory and anti-fibrotic therapeutic platform for life-threatening unchecked...

Read more

HanchorBio to Present at the ESMO Immuno-Oncology 2023 Annual Congress

December 1, 2023 7:00 AM

SAN FRANCISCO, CA and TAIPEI, TAIWAN / ACCESSWIRE / December 1, 2023 / HanchorBio Inc., a global clinical-stage biotechnology company focusing on the discovery and development of innovative immuno-biomedicines to treat a wide variety of patients suffering from hard-to-treat solid tumors or hematological malignancies, today announced the acceptance of poster presentation at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) 2023...

Read more

Biovica Receives License for Maryland State

December 1, 2023 2:20 AM

UPPSALA, SWEDEN / ACCESSWIRE / December 1, 2023 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, active in cancer diagnostics, today announces that the company has received a license for Maryland state, the 18th largest state in the US. The license means that Biovica can now perform analysis and report patient samples from all US states, except for New York and Washington DC."Our reach in the United States is steadily...

Read more

Longwood Healthcare Leaders San Francisco CEO to Convene Life Science Thought Leaders Prior to JPM

November 30, 2023 7:00 AM

BOSTON, MA / ACCESSWIRE / November 30, 2023 / Longwood Fund, an early-stage life science venture firm, will convene top biopharmaceutical leaders for two days of off-the-record discussions, January 6-7, 2024, the weekend immediately prior to the 42nd Annual JP Morgan Health Care Conference. Co-hosted by Stanford School of Medicine Dean Lloyd Minor and former Stanford President Marc Tessier-Lavigne, the meeting is held at the Four Seasons Hotel...

Read more

Nascent Biotech Granted Japanese Patent for Crossing Blood-Brain Barrier

November 29, 2023 8:00 AM

NORTH PALM BEACH, FL / ACCESSWIRE / November 29, 2023 / Nascent Biotech, Inc. (OTC:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce the Company has been issued a "Method-of-Use" patent from the Japanese Patent Office ("JPO") for its primary asset, Pritumumab ("PTB")....

Read more

FluoGuide A/S Publishes Interim Report for the Period January - September 2023

November 29, 2023 2:20 AM

KØBENHAVN, DENMARK / ACCESSWIRE / November 29, 2023 / FluoGuide A/S (STO:FLUO) Copenhagen, Denmark, 29 November 2023 - FluoGuide A/S ("FluoGuide" or the "Company") today releases its results for the period 1 January - 30 September 2023. The Q3 report is available as an attached document to this press release and on FluoGuide's website.In Q3 2023, FluoGuide completed patient recruitment for two clinical phase II trials of FG001, in aggressive...

Read more

Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-development of BupiZenge(TM) in the United States

November 28, 2023 8:15 AM

Collaboration Aims to Accelerate Development of BupiZenge™, a Novel Pain Treatment for Oral Mucositis Associated with Cancer TreatmentSAN DIEGO, CA and STOCKHOLM, SWEDEN / ACCESSWIRE / November 28, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, and OncoZenge AB ("OncoZenge") (STO:ONCOZ), a clinical-stage company...

Read more

AmplifyBio Expands Its Vision: Launches Advanced Therapy Manufacturing Enablement Center in New Albany, Ohio

November 28, 2023 7:00 AM

NEW ALBANY, OH / ACCESSWIRE / November 28, 2023 / AmplifyBio, a leading contract research organization, is announcing the opening of a new business unit to further expand its reach into the manufacturing of next-generation therapies that include cell, gene, mRNA, and other advanced modalities. The Amplify Manufacturing Enablement Center (AMEC), located 30 minutes from their West Jefferson headquarters in New Albany, Ohio, will comprise...

Read more

AbTherx Appoints David Meininger, PhD, MBA as Chief Business Officer

November 28, 2023 6:00 AM

Biopharma executive with proven track record brings substantial strategy, business development, and licensing experience to AbTherx leadership teamMOUNTAIN VIEW, CA / ACCESSWIRE / November 28, 2023 / AbTherx, a privately held biotech company with innovative technologies that enable and accelerate antibody discovery, today announced the appointment of David Meininger, PhD, MBA to the newly created position of Chief Business Officer. Dr. Meininger...

Read more